论文部分内容阅读
目的:评价加重组血管内皮抑素(恩度)联合化疗治疗晚期结直肠癌的疗效及不良反应。方法:30例晚期结直癌患者被随机分为治疗组和对照组。治疗组采用FOLFOX4方案+恩度:L-OHP 85 mg/m~2,静脉滴注2 h,第1天:LV 100 mg/m~2,静脉滴注,第1、2天;5-Fu 400 mg/m~2,静脉推注,600 mg/m~2,静脉滴注,第1、2天;恩度7.5 mg/m~2,静脉推注,3～4 h,第1～14天。对照组采用FOLFOX4方案化疗,剂量、方法与治疗相同。结果:治疗组和对照组的有效率分别为26.6%和13.3%(P=0.001);中位疾病进展时间(TTP)分别为7.9个月和4.3个月(P<0.0001)。治疗组和对照组副反应发生率比较,差异无统计学意义(P>0.05)。结论:恩度与FOLFOX4方案联合能显著提高晚期结直肠癌的PFS,且不增加治疗后的不良反应的发生率。
Objective: To evaluate the efficacy and adverse reactions of exacerbation of endostatin (Endostar) in combination with chemotherapy for advanced colorectal cancer. Methods: Thirty patients with advanced colorectal cancer were randomly divided into treatment group and control group. The treatment group with FOLFOX4 program + endurance: L-OHP 85 mg / m ~ 2, intravenous infusion of 2 h, the first day: LV 100 mg / m ~ 2, intravenous infusion, 400 mg / m ~ 2, intravenous injection, 600 mg / m ~ 2, intravenous infusion, on the first and second days; Endurance 7.5 mg / m ~ 2, intravenous injection, 3-4 h, day. Control group using FOLFOX4 regimen chemotherapy, the same dose, method and treatment. Results: The effective rates of treatment group and control group were 26.6% and 13.3%, respectively (P = 0.001). The median time to progression of disease (TTP) was 7.9 months and 4.3 months respectively (P <0.0001). There was no significant difference in the incidence of side effects between the treatment group and the control group (P> 0.05). Conclusions: Endostar combined with FOLFOX4 regimen can significantly increase the PFS of advanced colorectal cancer without increasing the incidence of adverse reactions after treatment.